The DOI matches its Crossref record; 82 of the 84 references it cites were found in a registry or an index.
Gene Therapy Using Adeno-Associated Virus Vectors
Open accessAbstract
SUMMARY: The unique life cycle of adeno-associated virus (AAV) and its ability to infect both nondividing and dividing cells with persistent expression have made it an attractive vector. An additional attractive feature of the wild-type virus is the lack of apparent pathogenicity. Gene transfer studies using AAV have shown significant progress at the level of animal models; clinical trials have been noteworthy with respect to the safety of AAV vectors. No proven efficacy has been observed, although in some instances, there have been promising observations. In this review, topics in AAV biology are supplemented with a section on AAV clinical trials with emphasis on the need for a deeper understanding of AAV biology and the development of efficient AAV vectors. In addition, several novel approaches and recent findings that promise to expand AAV's utility are discussed, especially in the context of combining gene therapy ex vivo with new advances in stem or progenitor cell biology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The virus itself is able to efficiently infect cells while provoking little to no innate or adaptive immune response or associated toxicity, at least upon first treatment with a serotype (Daya and Berns, 2008).”
From Delivering CRISPR: a review of the challenges and approaches (2018) · cites this paper as Daya and Berns, 2008
In the citing paper
“Eighty-four percent of genome sequence homology exists between AAV2 and AAV9, whereas the sequences of AAV2 and AAV5 have a 54% homology and AAV9 and AAV5 have a 46% homology.38,39”
From Systemic and local immune responses to intraocular AAV vector administration in non-human primates (2022) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406 · cited 1×
“AAV-2 gains entry into target cells by using the cellular receptor heparan sulfate proteoglycan ( 62 ).”
BackgroundKaplitt, M. G., Feigin, A., Tang, C., Fitzsimons, H. L., Mattis, P., Lawlor, P. A., Bland, R. J., Young, D., Strybing, K., Eidelberg, D., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60982-9 · Cited by 1,067
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 912
Site-specific integration by adeno-associated virus.
Kotin, R. M., Siniscalco, M., Samulski, R. J., Zhu, X. D., Hunter, L., Laughlin, C. A., McLaughlin, S., Muzyczka, N., Rocchi, M., & Berns, K. I. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.6.2211 · Cited by 868
Self-citationSite-specific integration by adeno-associated virus.
Linden, R. M., Ward, P., Giraud, C., Winocour, E., & Berns, K. I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11288 · Cited by 805
Self-citationFerrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761 · cited 1×
“Inefficient AAV trafficking (30) and second-strand synthesis (19) have been identified as being ratelimiting factors in AAV gene expression.”
BackgroundAAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
McCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735
Nucleotide sequence and organization of the adeno-associated virus 2 genome
Srivastava, A., Lusby, E. W., & Berns, K. I. (1983) · Journal of Virology · doi:10.1128/jvi.45.2.555-564.1983 · Cited by 721
Self-citationαVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711 · cited 1×
“Internalization is enhanced by interactions with one or more of at least six known coreceptors including #V$5 integrins (63), fibroblast growth factor receptor 1 (53), hepatocyte growth factor receptor (35), #v$1 integrin (7), and laminin receptor (3).”
BackgroundImmune responses to adenovirus and adeno-associated virus in humans
Chirmule, N., Propert, K. J., Magosin, S. A., Qian, Y., Qian, R., & Wilson, J. M. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300994 · Cited by 684
Recombinant adeno-associated virus for muscle directed gene therapy
Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., & Wilson, J. M. (1997) · Nature Medicine · doi:10.1038/nm0397-306 · Cited by 654 · cited 1×
“Nab to AAV have been to show limit AAV transduction in liver (47) and lung (28); however, no such effect was seen in muscle (21), brain (43), and retina (5).”
BackgroundHerzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554
Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors
Bartlett, J. S., Wilcher, R., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.6.2777-2785.2000 · Cited by 532
New recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487 · cited 1×
“The discovery of additional AAV serotypes is one possibility (24).”
BackgroundHerzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474 · cited 1×
“A factor IX AAV vector could be used to “cure” mice with hemophilia B (31) and, more excitingly, also performed well in a canine model of hemophilia (32).”
MethodHuman fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., & Srivastava, A. (1999) · Nature Medicine · doi:10.1038/4758 · Cited by 443
Akache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H., & Kay, M. A. (2006) · Journal of Virology · doi:10.1128/jvi.00878-06 · Cited by 430
Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors
Zaiss, A.-K., Liu, Q., Bowen, G. P., Wong, N. C. W., Bartlett, J. S., & Muruve, D. A. (2002) · Journal of Virology · doi:10.1128/jvi.76.9.4580-4590.2002 · Cited by 394
Moss, R. B., Rodman, D., Spencer, L. T., Aitken, M. L., Zeitlin, P. L., Waltz, D., Milla, C., Brody, A. S., Clancy, J. P., Ramsey, B., et al. (2004) · Chest · doi:10.1378/chest.125.2.509 · Cited by 390
Weitzman, M. D., Kyöstiö, S. R., Kotin, R. M., & Owens, R. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.5808 · Cited by 379
Girod, A., Wobus, C. E., Zádori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, J. A., & Hallek, M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-5-973 · Cited by 354 · cited 1×
“Interestingly, a conserved phospholipase A2 motif identified in the N terminus of the VP1 protein was reported to be important for successful infection ( 27 ).”
BackgroundTrans-splicing vectors expand the utility of adeno-associated virus for gene therapy
Yan, Z., Zhang, Y., Duan, D., & Engelhardt, J. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6716 · Cited by 305 · cited 1×
“Several novel AAV vector technologies have been developed to either increase the genome capacity for AAV or enhance gene expression (Fig. 3). The idea of trans-splicing AAV vectors has been used to increase AAV vector capacity ( 74 ).”
Flotte, T., Carter, B., Conrad, C., Guggino, W., Reynolds, T., Rosenstein, B., Taylor, G., Walden, S., & Wetzel, R. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.9-1145 · Cited by 279
Sanlioglu, S., Benson, P. K., Yang, J., Atkinson, E. M., Reynolds, T., & Engelhardt, J. F. (2000) · Journal of Virology · doi:10.1128/jvi.74.19.9184-9196.2000 · Cited by 269 · cited 1×
“Moreover, cellular signaling involving the activation of the Rac1 protein and the phosphatidylinositol 3-kinase pathway is necessary for intracellular trafficking of AAV particles using microtubules ( 57 ).”
BackgroundHepatocyte Growth Factor Receptor Is a Coreceptor for Adeno-Associated Virus Type 2 Infection
Kashiwakura, Y., Tamayose, K., Iwabuchi, K., Hirai, Y., Shimada, T., Matsumoto, K., Nakamura, T., Watanabe, M., Oshimi, K., & Daida, H. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.609-614.2005 · Cited by 246 · cited 1×
“Internalization is enhanced by interactions with one or more of at least six known coreceptors including V5 integrins (63), fibroblast growth factor receptor 1 (53), hepatocyte growth factor receptor ( 35 ), v1 integrin (7), and laminin receptor (3).”
BackgroundFlotte, T. R., Zeitlin, P. L., Reynolds, T. C., Heald, A. E., Pedersen, P., Beck, S., Conrad, C. K., Brass-Ernst, L., Humphries, M., Sullivan, K., et al. (2003) · Human Gene Therapy · doi:10.1089/104303403322124792 · Cited by 246
Aitken, M. L., Moss, R. B., Waltz, D. A., Dovey, M. E., Tonelli, M. R., McNamara, S. C., Gibson, R. L., Ramsey, B. W., Carter, B. J., & Reynolds, T. C. (2001) · Human Gene Therapy · doi:10.1089/104303401753153956 · Cited by 239 · cited 1×
“Thirteen protocols have been approved for phase I and phase II clinical trials using an AAV vector (2, 22, 23, 46, 66).”
MethodCharacterization of Adeno-Associated Virus Genomes Isolated from Human Tissues
Schnepp, B. C., Jensen, R. L., Chen, C.-L., Johnson, P. R., & Clark, K. R. (2005) · Journal of Virology · doi:10.1128/jvi.79.23.14793-14803.2005 · Cited by 231 · cited 1×
“Thus, current recombinant AAV (rAAV) vectors persist primarily as extrachromosomal elements (1, 59).”
BackgroundBartlett, J. S., Kleinschmidt, J., Boucher, R. C., & Samulski, R. J. (1999) · Nature Biotechnology · doi:10.1038/6185 · Cited by 230
Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus
Wagner, J. A., Reynolds, T., Moran, M. L., Moss, R. B., Wine, J. J., Flotte, T. R., & Gardner, P. (1998) · The Lancet · doi:10.1016/s0140-6736(05)77740-0 · Cited by 225 · cited 1×
“Thirteen protocols have been approved for phase I and phase II clinical trials using an AAV vector (2, 22, 23, 46, 66).”
MethodIn vivo model of adeno-associated virus vector persistence and rescue
Afione, S. A., Conrad, C. K., Kearns, W. G., Chunduru, S., Adams, R., Reynolds, T. C., Guggino, W. B., Cutting, G. R., Carter, B. J., & Flotte, T. R. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3235-3241.1996 · Cited by 223 · cited 1×
“Thus, current recombinant AAV (rAAV) vectors persist primarily as extrachromosomal elements (1, 59).”
BackgroundPereira, D. J., McCarty, D. M., & Muzyczka, N. (1997) · Journal of Virology · doi:10.1128/jvi.71.2.1079-1088.1997 · Cited by 208 · cited 1×
“Specifically, they positively and negatively regulate AAV gene expression in the presence or absence of helper virus, respectively, and are required for DNA replication (48).”
BackgroundHeparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208 · cited 1×
“it was discovered that the AAV-2 capsid heparin binding motif was responsible for T-cell activation (65).”
BackgroundHalbert, C. L., Standaert, T. A., Wilson, C. B., & Miller, A. D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9795-9805.1998 · Cited by 203 · cited 2×
“Interestingly, the humoral response to AAV may be T-cell dependent; the inhibition of T-cell function using anti-CD4 antibodies prevents Nab formation and allows vector readministration (14, 28, 40).”
BackgroundBleker, S., Sonntag, F., & Kleinschmidt, J. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.4.2528-2540.2005 · Cited by 200 · cited 1×
“Mutational analysis of the AAV capsid structure indicated that the fivefold pore structure may also serve as the site for phospholipase domain presentation during viral infection ( 10 ).”
BackgroundChirmule, N., Xiao, W., Truneh, A., Schnell, M. A., Hughes, J. V., Zoltick, P., & Wilson, J. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.5.2420-2425.2000 · Cited by 198
Targeted Gene Delivery to Vascular Tissue In Vivo by Tropism-Modified Adeno-Associated Virus Vectors
White, S. J., Nicklin, S. A., Büning, H., Brosnan, M. J., Leike, K., Papadakis, E. D., Hallek, M., & Baker, A. H. (2004) · Circulation · doi:10.1161/01.cir.0000109697.68832.5d · Cited by 193 · cited 1×
“This approach has been used successfully to target endothelial cells (61, 69 ).”
MethodDynamin Is Required for Recombinant Adeno-Associated Virus Type 2 Infection
Duan, D., Li, Q., Kao, A. W., Yue, Y., Pessin, J. E., & Engelhardt, J. F. (1999) · Journal of Virology · doi:10.1128/jvi.73.12.10371-10376.1999 · Cited by 186 · cited 1×
“Cells defective for dynamin significantly hindered AAV-2 infection, suggesting that AAV is endocytosed into clathrin-coated vesicles (15).”
BackgroundAsokan, A., Hamra, J. B., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.00843-06 · Cited by 183
Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease
Feigin, A., Kaplitt, M. G., Tang, C., Lin, T., Mattis, P., Dhawan, V., During, M. J., & Eidelberg, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706006104 · Cited by 181 · cited 1×
“(17) described a study in which 12 patients with advanced Parkinson’s disease had an AAV vector carrying a transgene encoding glutamic acid decarboxylase injected into the subthalamic nucleus on one side.”
BackgroundBrockstedt, D. G., Podsakoff, G. M., Fong, L., Kurtzman, G., Mueller-Ruchholtz, W., & Engleman, E. G. (1999) · Clinical Immunology · doi:10.1006/clim.1999.4724 · Cited by 165
Li, Z., Zhao, W., Wu, J., Li, B., Zolotukhin, S., Govindasamy, L., Agbandje‐McKenna, M., & Srivastava, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300170 · Cited by 156
Tan, I., Ng, C. H., Lim, L., & Leung, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102615200 · Cited by 156 · cited 1×
“The exact function of this gene is not clear, but its product has been shown to be involved in actin organization (64).”
BackgroundComprehensive Analysis of Ebola Virus GP1 in Viral Entry
Manicassamy, B., Wang, J., Jiang, H., & Rong, L. (2005) · Journal of Virology · doi:10.1128/jvi.79.8.4793-4805.2005 · Cited by 155
Ponnazhagan, S., Mahendra, G., Kumar, S., Thompson, J. A., & Castillas, M. (2002) · Journal of Virology · doi:10.1128/jvi.76.24.12900-12907.2002 · Cited by 147
Manning, W. C., Zhou, S., Bland, M. P., Escobedo, J. A., & Dwarki, V. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.4-477 · Cited by 140 · cited 1×
“Interestingly, the humoral response to AAV may be T-cell dependent; the inhibition of T-cell function using anti-CD4 antibodies prevents Nab formation and allows vector readministration (14, 28, 40).”
BackgroundSchmidt, M., Afione, S. A., & Kotin, R. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.20.9441-9450.2000 · Cited by 132
Qing, K., Hansen, J., Weigel-Kelley, K. A., Tan, M., Zhou, S., & Srivastava, A. (2001) · Journal of Virology · doi:10.1128/jvi.75.19.8968-8976.2001 · Cited by 126 · cited 2×
“Interestingly, the binding of cellular protein FKBP52 to the AAV ITR inhibits second-strand synthesis, and this inhibition is dependent on the phosphorylation state of FKBP52 (51, 52, 80).”
BackgroundCharacterization of cell lines that inducibly express the adeno-associated virus Rep proteins
Yang, Q., Chen, F., & Trempe, J. P. (1994) · Journal of Virology · doi:10.1128/jvi.68.8.4847-4856.1994 · Cited by 125
Pre-existing AAV Capsid-specific CD8+ T Cells are Unable to Eliminate AAV-transduced Hepatocytes
Li, H., Murphy, S. L., Giles‐Davis, W., Edmonson, S. A., Xiang, Z., Li, Y., Lasaro, M. O., High, K. A., & Ertl, H. C. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300090 · Cited by 119
Zhang, Y., Chirmule, N., Gao, G.-P., & Wilson, J. (2000) · Journal of Virology · doi:10.1128/jvi.74.17.8003-8010.2000 · Cited by 119
Site-specific integration by adeno-associated virus is directed by a cellular DNA sequence.
Giraud, C., Winocour, E., & Berns, K. I. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.10039 · Cited by 117 · cited 1×
“is necessary and sufficient to target AAV integration (26).”
BackgroundSelf-citationHauck, B., Zhao, W., High, K. A., & Xiao, W. (2004) · Journal of Virology · doi:10.1128/jvi.78.24.13678-13686.2004 · Cited by 117 · cited 1×
“Inefficient AAV trafficking (30) and second-strand synthesis (19) have been identified as being ratelimiting factors in AAV gene expression.”
BackgroundWang, L., Figueredo, J., Calcedo, R., Lin, J., & Wilson, J. M. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.001 · Cited by 113
A p5 integration efficiency element mediates Rep-dependent integration into AAVS1 at chromosome 19
Philpott, N. J., Gomos, J. B., Berns, K. I., & Falck-Pedersen, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182430299 · Cited by 113 · cited 1×
“These include the ITRs (in cis), Rep78 or Rep68 (in trans), and a 138-bp sequence termed the integration efficiency element (IEE), located within the P5 promoter in cis (49).”
BackgroundSelf-citationSite-Specific Integration of Functional Transgenes into the Human Genome by Adeno/AAV Hybrid Vectors
Recchia, A., Perani, L., Sartori, D., Olgiati, C., & Mavilio, F. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.003 · Cited by 109
Wu, J., Zhao, W., Zhong, L., Han, Z., Li, B., Ma, W., Weigel-Kelley, K. A., Warrington, K. H., & Srivastava, A. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.088 · Cited by 108
Adeno-associated virus site-specifically integrates into a muscle-specific DNA region
Dutheil, N., Shi, F., Dupressoir, T., & Linden, R. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.080079397 · Cited by 107 · cited 1×
“The AAVS1 locus is near several muscle-specific genes, TNNT1 and TNNI3 (16).”
BackgroundInfection of Purified Nuclei by Adeno-associated Virus 2
Hansen, J. J., Qing, K., & Srivastava, A. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0457 · Cited by 102
Akache, B., Grimm, D., Shen, X., Fuess, S., Yant, S. R., Glazer, D. S., Park, J., & Kay, M. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300053 · Cited by 98
Reich, S. J., Auricchio, A., Hildinger, M., Glover, E., Maguire, A. M., Wilson, J. M., & Bennett, J. (2003) · Human Gene Therapy · doi:10.1089/10430340360464697 · Cited by 96 · cited 1×
“retina (55), the lung (39), and, more recently, muscle (25).”
BackgroundArnold, G. S., Sasser, A. K., Stachler, M. D., & Bartlett, J. S. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.02.014 · Cited by 88
Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain
Mastakov, M. Y., Baer, K., Symes, C. W., Leichtlein, C. B., Kotin, R. M., & During, M. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.16.8446-8454.2002 · Cited by 87
Liu, X., Luo, M., Zhang, L. N., Yan, Z., Žák, R., Ding, W., Mansfield, S. G., Mitchell, L. G., & Engelhardt, J. F. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1116 · Cited by 71
Ghosh, A., Yue, Y., & Duan, D. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.835 · Cited by 69
Anand, V., Duffy, B., Yang, Z., Dejneka, N. S., Maguire, A. M., & Bennett, J. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0525 · Cited by 69 · cited 1×
“Nab to AAV have been to show limit AAV transduction in liver (47) and lung (28); however, no such effect was seen in muscle (21), brain (43), and retina (5).”
BackgroundMurphy, S. L., Li, H., Zhou, S., Schlachterman, A., & High, K. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300334 · Cited by 67
Stachler, M. D., & Bartlett, J. S. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302738 · Cited by 67
Qing, K., Li, W., Li, Z., Tan, M., Hansen, J. J., Weigel-Kelley, K. A., Chen, L., Yöder, M. C., & Srivastava, A. (2003) · Journal of Virology · doi:10.1128/jvi.77.4.2741-2746.2003 · Cited by 65
Development of Animal Models for Adeno-Associated Virus Site-Specific Integration
Rizzuto, G., Gorgoni, B., Cappelletti, M., Lazzaro, D., Gloaguen, I., Poli, V., Sgura, A., Cimini, D., Ciliberto, G., Cortese, R., et al. (1999) · Journal of Virology · doi:10.1128/jvi.73.3.2517-2526.1999 · Cited by 48 · cited 1×
“ing that the AAVS1 open-chromatin structure is maintained in vivo and that the cellular factors that mediate site-specific integration are present in nondividing cells (56).”
BackgroundA 16 bp Rep Binding Element is Sufficient for Mediating Rep-dependent Integration into AAVS1
Feng, D., Chen, J., Yue, Y., Zhu, H., Xue, J., & Jia, W. W.-G. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.01.029 · Cited by 33 · cited 1×
“It is unclear if the entire 138-bp IEE in P5 is required, since a recent study showed that a 16-bp RBE in P5 is sufficient (18).”
BackgroundFischer, A., Hacein‐Bey‐Abina, S., Lagresle‐Peyrou, C., Garrigue, A., & Cavazzana, M. (2005) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)33504-6 · Cited by 28
Emerging Role of Regulatory T Cells in Gene Transfer
Cao, O., Furlan-Freguia, C., Arruda, V. R., & Herzog, R. W. (2007) · Current Gene Therapy · doi:10.2174/156652307782151506 · Cited by 26 · cited 1×
“Other possible advances include a better understanding of the host response and the requirements for the induction of tolerance and the development of more efficient systems for the production of AAV vectors (12).”
BackgroundRAC Reviews Serious Adverse Event Associated with AAV Therapy Trial
Williams, D. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300352 · Cited by 26
Zhao, W., Wu, J., Zhong, L., & Srivastava, A. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302886 · Cited by 19
Zhang, C., Cortez, N. G., & Berns, K. I. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.056 · Cited by 18
Self-citationGene Transfer an Unlikely Contributor to Patient's Death
Kaiser, J. (2007) · Science · doi:10.1126/science.318.5856.1535 · Cited by 14 · cited 1×
“A much more serious problem arose in a clinical trial involving rheumatoid arthritis (33, 70).”
BackgroundAdeno-Associated Virus Site-Specific Integration Is Regulated by TRP-185
Yamamoto, N., Suzuki, M., Kawano, M., Inoue, T., Takahashi, R., Tsukamoto, H., Enomoto, T., Yamaguchi, Y., Wada, T., & Handa, H. (2006) · Journal of Virology · doi:10.1128/jvi.02014-06 · Cited by 5
Research works printed but not linked: 1
- Fischer, A., S. Hacein-Bey-Abina, C. Lagresle, A. Garrigue, and M. Cavazana-Calvo. 2005. Gene therapy of severe combined immunodeficiency disease: proof of efficiency and safety issues. Bull. Acad. Natl. Med.189:779-785. (In French.)
Cited by
Delivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185
“The virus itself is able to efficiently infect cells while provoking little to no innate or adaptive immune response or associated toxicity, at least upon first treatment with a serotype (Daya and Berns, 2008).”
BackgroundTherapeutic strategies for enhancing angiogenesis in wound healing
Veith, A. P., Henderson, K., Spencer, A., Sligar, A. D., & Baker, A. B. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.09.010 · Cited by 1,021
“These viruses are characterized by low immunogenicity and the need for a helper virus to replicate [217].”
BackgroundMethodThe war against heart failure: the Lancet lecture
Braunwald, E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61889-4 · Cited by 811
State-of-the-art gene-based therapies: the road ahead
Kay, M. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2971 · Cited by 666
“The therapeutic expression cassette replaces rep and cap , leaving the viral inverted terminal repeats as the only viral sequence”
BackgroundAurnhammer, C., Haase, M., Muether, N., Hausl, M., Rauschhuber, C., Huber, I., Nitschko, H., Busch, U., Sing, A., Ehrhardt, A., et al. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.034 · Cited by 490
“…of AAV replication, the ITR sequences play a critical role as origins of replication, serving as priming sequences for the host cell DNA polymerase during second-strand synthesis, as well as being essential for genome packaging (Yan et al. , 2005; McAlister and Owens, 2007; Daya and Berns, 2008).”
Influential
Metadata
- Authors
- Daya, S., & Berns, K. I.
- Affiliations
- University of Florida (US)
- Corresponding author
- Berns, Kenneth I.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 2008-10
- Volume
- 21
- Issue
- 4
- Pages
- 583-593
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- PMC
- PMC2570152
- OpenAlex
- W2114741749
- Cited by
- 926
- References
- 84
- Citations by year
- 2026: 28 · 2025: 37 · 2024: 53 · 2023: 47 · 2022: 62 · 2021: 71 · 2020: 77 · 2019: 67 · 2018: 71 · 2017: 64 · 2016: 56 · 2015: 56 · 2014: 44 · 2013: 38 · 2012: 46
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Clinical Microbiology Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK058327, DK58327)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- adeno-associated virus, gene therapy vectors, persistent gene expression, vector safety, ex vivo gene therapy, stem cell gene therapy, progenitor cells
- MeSH terms
- Dependovirus, Animals, Humans, Transduction, Genetic, Genetic Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.